<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
FORM 10-Q
------------------
Quarterly report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1997 COMMISSION FILE NUMBER: 0-27242
----------------------------------
PHYSIO-CONTROL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 91-1673799
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
11811 WILLOWS ROAD N.E.
REDMOND, WASHINGTON 98052
(Address of principal executive offices)
(206) 867-4000
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:
Yes X No
----- -----
As of April 18, 1997, there were 17,154,441 shares of the Registrant's
Common Stock outstanding.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
1
<PAGE>
- --------------------------------------------------------------------------------
FORM 10-Q
MARCH 31, 1997
<TABLE>
<CAPTION>
Index Page
----- ----
<S> <C>
PART I. FINANCIAL INFORMATION
ITEM 1. Consolidated Financial Statements
- Consolidated Balance Sheets as of March 31, 1997
and December 31, 1996............................................................3
- Consolidated Statements of Operations for the three months
ended March 31, 1997 and 1996....................................................4
- Consolidated Statement of Changes in Stockholders' Equity
for the three months ended March 31, 1997........................................5
- Consolidated Statements of Cash Flows for the three months
ended March 31, 1997 and 1996....................................................6
- Notes to Consolidated Financial Statements.......................................7
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations............................................................9
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings................................................................11
ITEM 6. Exhibits and Reports on Form 8-K.................................................11
</TABLE>
2
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEETS
(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
...............................................................................
<TABLE>
<CAPTION>
MARCH 31, 1997 DECEMBER 31, 1996
-------------- -----------------
ASSETS (UNAUDITED)
<S> <C> <C>
CURRENT ASSETS
Cash and cash equivalents $4,324 $3,336
Accounts receivable, net 38,187 38,869
Inventories, net 34,843 31,811
Prepaid income taxes 3,111 3,967
Prepaid expenses 1,878 1,401
------- -------
Total current assets 82,343 79,384
NONCURRENT ASSETS
Other assets 1,086 1,180
Deferred income taxes 2,175 2,175
Property, plant and equipment, net 14,494 13,123
------- -------
TOTAL ASSETS $100,098 $95,862
------- -------
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $11,366 $9,260
Accrued liabilities 16,261 19,146
Deferred income taxes 494 494
------- -------
Total current liabilities 28,121 28,900
------- -------
NONCURRENT LIABILITIES
Long-term debt 22,136 21,031
Unfunded pension obligations 1,540 1,711
------- -------
Total noncurrent liabilities 23,676 22,742
------- -------
Commitments and contingencies (Note 4)
STOCKHOLDERS' EQUITY
Preferred stock, par value $0.01 per share, 5,000,000
shares authorized, no shares issued or outstanding
Common stock, voting, par value $0.01 per share,
40,000,000 shares authorized; 17,154,441 and 17,020,245
shares issued and outstanding, respectively 172 170
Additional paid-in capital 27,457 25,707
Retained earnings 20,751 18,098
Equity adjustment from foreign currency translation (79) 245
------- -------
Total stockholders' equity 48,301 44,220
------- -------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $100,098 $95,862
- -------------------------------------------------------------------------- -------
</TABLE>
..........................................................................
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
3
<PAGE>
- -------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(UNAUDITED)
...............................................................................
QUARTER ENDED QUARTER ENDED
MARCH 31, 1997 MARCH 31, 1996
-------------- --------------
Net sales $40,727 $42,755
Cost of sales 19,846 21,432
-------------- --------------
Gross profit 20,881 21,323
-------------- --------------
Research and development 5,237 4,638
Sales and marketing 8,854 7,795
General and administrative 2,014 3,042
-------------- --------------
Operating expense 16,105 15,475
-------------- --------------
Interest expense (459) (426)
Other expense, net (236) (276)
-------------- --------------
Other expense (695) (702)
-------------- --------------
Income before income taxes 4,081 5,146
Income tax expense (1,428) (1,750)
-------------- --------------
Net income $2,653 $3,396
-------------- --------------
Net earnings per common and
common equivalent shares $0.15 $0.19
Weighted average number of common
and common equivalent shares outstanding 18,080,919 17,930,882
- -------------------------------------------------------------- -------------
..........................................................................
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
4
<PAGE>
- -------------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(DOLLARS IN THOUSANDS, EXCEPT SHARE DATA)
(UNAUDITED)
...............................................................................
<TABLE>
<CAPTION>
EQUITY
COMMON STOCK ADJUSTMENT
(VOTING) ADDITIONAL FROM FOREIGN
------------------------- PAID-IN RETAINED CURRENCY
SHARES DOLLARS CAPITAL EARNINGS TRANSLATION TOTAL
---------- ------- ---------- -------- ------------ --------
<S> <C> <C> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1996 17,020,245 $170 $25,707 $18,098 $245 $44,220
Issuance of common shares 46,791 1 915 916
Stock issued upon exercise
of options 87,405 1 407 408
Income tax benefit from
exercise of stock options 428 428
Equity adjustment from
foreign currency translation (324) (324)
Net income 2,653 2,653
---------- ------- ---------- -------- ------------ --------
BALANCE AT MARCH 31, 1997 17,154,441 $172 $27,457 $20,751 ($79) $48,301
- --------------------------------------------- ------- ---------- -------- ------------ --------
</TABLE>
..........................................................................
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
5
<PAGE>
- -------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DOLLARS IN THOUSANDS)
(UNAUDITED)
...............................................................................
<TABLE>
<CAPTION>
QUARTER ENDED QUARTER ENDED
MARCH 31, 1997 MARCH 31, 1996
-------------- --------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $2,653 $3,396
ADJUSTMENTS TO RECONCILE NET INCOME TO NET CASH
PROVIDED BY (USED IN) OPERATING ACTIVITIES:
Depreciation and amortization 421 288
Decrease (increase) in receivables 682 (4,238)
(Increase) decrease in inventories (3,032) 1,268
Decrease in prepaid income taxes 856 1,712
Increase in prepaid expense and other assets (443) (1,510)
Increase (decrease) in accounts payable 2,106 (2,401)
Decrease in accrued and other liabilities (3,056) (4,095)
-------------- --------------
Net cash provided by (used in) operating activities 187 (5,580)
-------------- --------------
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment (1,732) (1,133)
-------------- --------------
Net cash used in investing activities (1,732) (1,133)
-------------- --------------
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings under revolving debt 14,862 18,973
Repayments on revolving debt (13,757) (10,474)
Net proceeds from issuance of common stock 1,324 33
Income tax benefit from issuance of common stock 428
-------------- --------------
Net cash provided by financing activities 2,857 8,532
-------------- --------------
Effect of foreign currency translation (324) (95)
-------------- --------------
Net increase in cash and cash equivalents 988 1,724
Cash and cash equivalents at beginning of period 3,336 4,575
-------------- --------------
Cash and cash equivalents at end of period $4,324 $6,299
- ------------------------------------------------------------------------------------- --------------
</TABLE>
..........................................................................
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.
6
<PAGE>
- -------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(UNAUDITED)
...............................................................................
NOTE 1. GENERAL
The consolidated financial statements as of March 31, 1997 and for the three
month period then ended are unaudited and reflect all adjustments (consisting
only of normal recurring adjustments) which are, in the opinion of management,
necessary for a fair presentation of the financial position and operating
results for the interim period. The consolidated financial statements should be
read in conjunction with the Company's Annual Report on Form 10-K for the year
ended December 31, 1996. The results of operations for the three months ended
March 31, 1997 are not necessarily indicative of the results for the entire
fiscal year ending December 31, 1997.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
EARNINGS PER SHARE
Net earnings per common and common equivalent share is computed using the
weighted average number of shares outstanding adjusted for the incremental
shares attributed to outstanding options to purchase common stock. Fully
diluted net earnings per common and common equivalent share is not materially
different from primary net earnings per common and common equivalent share and
is therefore not presented.
NOTE 3. INVENTORIES
Inventories consist of the following:
MARCH 31, 1997 DECEMBER 31, 1996
-------------- -----------------
Finished products $21,656 $18,734
Purchased parts and assemblies in process 7,275 6,534
Service parts 7,976 9,037
-------------- -----------------
36,907 34,305
Less inventory allowances (2,064) (2,494)
-------------- -----------------
TOTAL INVENTORIES $34,843 $31,811
-------------- -----------------
7
<PAGE>
- -------------------------------------------------------------------------------
NOTE 4. COMMITMENTS AND CONTINGENCIES
LITIGATION
The Company is party to certain legal actions arising in the ordinary course of
its business. The Company's estimates of these exposures are based primarily on
historical claims experience. The Company expects settlements related to these
claims to be paid over the next several years. The majority of the costs
associated with defending and disposing of these suits are covered by insurance.
On November 13, 1995, the Company initiated litigation in Washington State Court
against Heartstream, Inc. ("Heartstream"), a company formed to develop,
manufacture and market defibrillators, as well as certain individuals who were
formerly employed by the Company and who are founders of and employees of
Heartstream. The Company's claims are based on its belief that Heartstream and
such individuals have, among other things, misappropriated certain of the
Company's intellectual property and that such individuals have breached
contractual obligations to the Company. The Company received an answer to its
complaint from Heartstream and in its answer, Heartstream denies the Company's
claims and alleges certain counterclaims against the Company for, among other
things, monopolization of the industry and tortuous interference with business
opportunities. While the Company believes it has meritorious defenses against
the suit, the ultimate resolution of the matter could result in a loss of up to
$10 million. The parties are currently conducting discovery in this litigation
and a tentative trial date has been set for September, 1997.
Additionally, during January, 1997 Heartstream initiated litigation against the
Company in U.S. District Court for the Western District of Washington alleging
that the Company is infringing a Heartstream patent related to product self-test
features. The Company has filed an answer denying Heartstream's claims and
alleging certain counterclaims against Heartstream for infringement of a Company
self-test patent. Discovery is in the initial stages in this litigation.
If the Company does not prevail in these litigations or otherwise successfully
resolve its claims, its ability to design and market certain future products may
be adversely affected. In addition, if a court were to find in favor of
Heartstream on its claims, the Company could be liable for significant damages.
In the opinion of management, the amount of ultimate liability with respect to
these actions will not materially affect the financial position of the Company.
8
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
- -------------------------------------------------------------------------------
Management's Discussion and Analysis of Financial Condition and Results of
Operation contains forward-looking statements that involve risks and
uncertainties. The Company's actual results may differ significantly from the
results discussed in the forward-looking statements due to many factors,
including, but not limited to, the effect of general economic conditions, the
impact of competitive products and pricing, customer demand, product
development, commercialization and technological difficulties, U.S. and foreign
regulatory requirements, the effects of accounting policies and financing
requirements, and other such risks and factors.
RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 1997 AND 1996
The Company reported worldwide sales of $40.7 million for the first quarter of
1997, reflecting a decrease of $2.0 million or 5% from the comparable 1996
quarter. Domestic sales for the current quarter aggregated $29.6 million, down
6% from the comparable 1996 quarter, and international sales of $11.2 million
were down 2% from the 1996 period. Worldwide equipment sales of $26.1 million
decreased 10% from the comparable 1996 quarter due primarily to softness in the
U.S. domestic hospital market. Worldwide service revenue of $6.9 million
increased slightly (1%) over the comparable prior year period, and supplies
(disposable and accessory) revenue of $7.7 million increased 11% due to a strong
demand for the Company's disposable products, primarily QUIK-COMBO electrodes.
The decrease in domestic sales between the comparable quarters was driven
primarily by the U.S. domestic hospital market. Out-of-hospital sales, however,
were essentially unchanged from the prior year quarter as sales from the
Company's new LIFEPAK 500 offset shortfalls in other products. Shipments of the
new LIFEPAK 500 defibrillator commenced during February 1997 and the product has
been well received within the market due to its light weight, low maintenance,
and simple operation. Internationally, sales decreased 2% from the prior year
quarter due to weaker sales in both Latin America and Europe.
During the first quarter of 1997, the Company reported worldwide product orders
of $37.1 million, up $1.6 million or 4% from the comparable 1996 quarter. The
increase in product orders was due to the introduction of the LIFEPAK 500
defibrillator as well as solid international performance. Domestic product
orders remained essentially unchanged from the comparable prior year period,
however, international orders increased 13% due to increased activity in the
Eastern European marketplace.
Gross profit of $20.9 million decreased $0.4 million during the current quarter
from $21.3 million during the comparable 1996 period. However, as a percentage
of sales, gross profit increased from 49.9% during the comparable 1996 quarter
to 51.3% in the 1997 quarter. The increase in gross profit was primarily
attributed to a favorable product mix, including the impact of LIFEPAK 500
sales, and a reduction in aggressive trade-in programs that had been offered
during the comparable 1996 period.
Research and development ("R&D") expenditures of $5.2 million increased 13%
during the current quarter from $4.6 million in the comparable 1996 quarter. As
a percentage of sales, R&D expenses increased from 11% in the 1996 quarter to
13% during the 1997 quarter. R&D expenditures increased due to the Company's
accelerated and continuing commitment to develop new products as well as conduct
ongoing research for future products and technology.
Sales and marketing expenditures of $8.9 million increased 14% from the
comparable 1996 quarter. The increase resulted from enhanced sales and
marketing efforts aimed at introducing the Company's new LIFEPAK 500 during
January and February 1997. In addition to product introduction costs,
international selling expense increased from the comparable 1996 quarter. The
Company has continued to commit resources to develop international marketing
strategy and marketshare.
9
<PAGE>
- -------------------------------------------------------------------------------
General and administrative expenditures of $2.0 million decreased 34% from the
comparable 1996 quarter mainly due to no counterpart to 1996 bonus accrual. As
a percentage of sales, general and administrative expenses decreased from 7%
during the comparable 1996 quarter to 5% during the current quarter.
On a combined basis, selling, general and administrative ("SG&A") expenses
during the first quarter of 1997 remained consistent with the comparable prior
quarter. As a percentage of sales, however, SG&A expenses increased slightly
from 25% during the comparable 1996 period to 27% during 1997, mainly
attributable to lower sales volume.
Other expenses, consisting primarily of interest expense, totaled $0.7 million
which remained consistent with the comparable 1996 quarter.
Income tax expense of $1.4 million reflected an increase in the Company's
effective tax rate from 34% in the comparable 1996 period to 35% during the
current period. The increase is primarily due to a lower percentage of
international income.
As a result of the above factors, net income for the first quarter of 1997 was
$2.7 million, a decrease of $0.7 million from the comparable 1996 quarter.
LIQUIDITY AND CAPITAL RESOURCES
For the three months ended March 31, 1997, the Company generated $0.2 million in
cash to finance operations compared with $5.6 million of cash used by operations
in the comparable 1996 quarter. During the current quarter, cash generated from
net income was primarily offset by an increase in inventory. The significant
use of cash reported in the 1996 quarter was due primarily to an increase in
trade accounts receivable as well as an decrease in trade accounts payable and
other liabilities.
Cash used for investing activities during the three months ended March 31, 1997
totaled $1.7 million. Consistent with the year ended 1996, the majority of the
Company's capital expenditures during the current quarter related to the final
stages of implementation of the Company's new computer business system.
Additional capital expenditures during the quarter related to research and
engineering equipment. The Company does not have any capital commitments
outside the ordinary course of business. The Company's principal working
capital requirements are financing accounts receivable and inventories. At
March 31, 1997, the Company had net working capital of $54.2 million, including
accounts receivable of $38.2 million, inventories of $34.8 million, accounts
payable of $11.4 million, and other accruals totaling $16.3 million.
The Company obtains its financing for operations through the use of a revolving
credit facility ("the Revolver") which is not to exceed $30.0 million. The
Revolver bears interest at the Company's option, at either (i) the lender's base
rate (the higher of such lender's prime rate or the federal funds rate plus
0.5%) or (ii) LIBOR plus 1.0%. Such rates are subject to increase in the event
that the Company does not meet certain leverage and interest coverage ratios.
At March 31, 1997, the average interest rate on amounts outstanding under the
Revolver was 6.5%. The Company's indebtedness under the Revolver is secured by
a first priority interest in and lien on all of the assets of Physio-Control
Corporation ("PCC"), a pledge by the Company on all of the outstanding common
stock of PCC and 65% of the outstanding stock of PCC's subsidiaries and other
guaranties and pledges as defined in the
10
<PAGE>
- -------------------------------------------------------------------------------
credit agreement. The credit agreement includes various affirmative and
negative covenants which require, among other things, that the Company maintain
certain debt to equity and net worth ratios, limitations on capital
expenditures, restrictions on the declaration and payment of dividends and
minimum earnings before interest, income taxes, depreciation and amortization.
At March 31, 1997, the Company had borrowing availability under the Revolver of
approximately $9.8 million after consideration of outstanding letters of credit
of $0.6 million, and was in compliance with all related loan covenants.
In addition, the Company has subordinated promissory notes payable to Eli Lilly
and Company totaling $2.5 million which originated in the acquisition of PCC and
certain foreign assets. Notes with a principal balance totaling $1.5 million
mature on January 31, 2001 and bear interest at LIBOR plus 3.25% . An
additional promissory note payable has a principal balance of $1.0 million,
matures on November 15, 1998 and bears interest at LIBOR plus 3.0%.
The Company believes that, based upon current levels of operations and
anticipated growth, funds generated from operations, together with other
available sources of liquidity, including borrowings under the credit facility,
will be sufficient over the next twelve months for the Company to make
anticipated capital expenditures and fund working capital requirements.
Approximately 27% of the Company's sales in the first quarter of 1997 were to
international customers and the Company expects that sales to international
customers will continue to represent a material portion of its sales. Certain
of the Company's international receivables are denominated in foreign currencies
and exchange rate fluctuations impact the carrying value of these receivables.
The Company has elected to hedge certain assets denominated in foreign
currencies with the purchase of forward contracts. Historically, fluctuations
in foreign currency exchange rates have not had a material effect on the
Company's results of operations and, with certain hedging activities, the
Company does not expect such fluctuations to be material in the foreseeable
future.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
There have been no material changes in the status of litigation reported in the
Company's Annual Report on Form 10-K for the year ended December 31, 1996. (See
Note 4 of the Notes to Consolidated Financial Statements in Part I, Item 1,
above).
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
Exhibit No. Description of Exhibit
- ----------- ----------------------
27.1 Financial Data Schedule
No reports on Form 8-K were filed during the quarter ended March 31, 1997.
11
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized to sign on behalf of the registrant and as
the principal financial officer thereof.
Dated: May 9, 1997
PHYSIO-CONTROL INTERNATIONAL CORPORATION
By /s/ Joseph J. Caffarelli
------------------------------
Joseph J. Caffarelli
Executive Vice President and Chief Financial Officer
12
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 4,324
<SECURITIES> 0
<RECEIVABLES> 38,934
<ALLOWANCES> (747)
<INVENTORY> 34,843
<CURRENT-ASSETS> 82,343
<PP&E> 16,555
<DEPRECIATION> (2,061)
<TOTAL-ASSETS> 100,098
<CURRENT-LIABILITIES> 28,121
<BONDS> 0
0
0
<COMMON> 172
<OTHER-SE> 48,129
<TOTAL-LIABILITY-AND-EQUITY> 100,098
<SALES> 40,727
<TOTAL-REVENUES> 40,727
<CGS> 19,846
<TOTAL-COSTS> 19,846
<OTHER-EXPENSES> 16,105
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 459
<INCOME-PRETAX> 4,081
<INCOME-TAX> 1,428
<INCOME-CONTINUING> 2,653
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 2,653
<EPS-PRIMARY> 0.15
<EPS-DILUTED> 0.15
</TABLE>
